Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 -1.42%80 Return-on-Tangible-Asset is 13.45% as of Mar. 2026, which is 184% above its 10-year median of 4.74. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$29.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, Apex Biotechnology ranks better than 90.32% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Apex Biotechnology's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$325 Mil. Apex Biotechnology's average total tangible assets for the quarter that ended in Mar. 2026 was NT$2,418 Mil. Therefore, Apex Biotechnology's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 13.45%.
The historical rank and industry rank for Apex Biotechnology's Return-on-Tangible-Asset or its related term are showing as below:
TPE:1733'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.12 Med: 4.74 Max: 7.95
Current: 7.67
During the past 13 years, Apex Biotechnology's highest Return-on-Tangible-Asset was 7.95%. The lowest was 0.12%. And the median was 4.74%.
TPE:1733's Return-on-Tangible-Asset is ranked better than 90.32% of 1415
companies
in the Biotechnology industry
Industry Median: -35.49
vs TPE:1733: 7.67
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Apex Biotechnology Return-on-Tangible-Asset Related Terms
Apex Biotechnology Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Apex Biotechnology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.45% mean?
Apex Biotechnology (TPE:1733) has a Return-on-Tangible-Asset of 13.45% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Apex Biotechnology and its competitors. This is 184% above median its historical median of 4.74. Over the past decade, Apex Biotechnology's Return-on-Tangible-Asset has ranged from 0.12 to 7.95. According to the industry distribution chart, Apex Biotechnology ranks #137 out of 1415 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Apex Biotechnology's Return-on-Tangible-Asset too high?
Apex Biotechnology's current Return-on-Tangible-Asset of 13.45% is 184% above median its 10-year median of 4.74. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 7.95. Based on the distribution chart, Apex Biotechnology ranks #137 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #137 out of 1415 companies for Return-on-Tangible-Asset. This places Apex Biotechnology in the top 10% of its industry — outperforming the majority of peers. Historically, Apex Biotechnology's own Return-on-Tangible-Asset has ranged from 0.12 to 7.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Return-on-Tangible-Asset is 13.45%, which is 184% above median its own 10-year median of 4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.80, compared to a current price of NT$31.30 — trading 5% above its estimated fair value. The current Return-on-Tangible-Asset is 13.45%, which is 184% above median its 10-year median of 4.74. Apex Biotechnology's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Return-on-Tangible-Asset is 13.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$31.30 is trading 5% above its estimated GF Value™ of NT$29.80.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Return-on-Tangible-Asset: 13.45% (184% above median its 10-year median of 4.74)
GF Value™: NT$29.80 vs. price of NT$31.30 (5% above fair value)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score
Get the complete analysis for TPE:1733
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
